Xing Li Phones & Addresses
-
Whitestone, NY
-
Philadelphia, PA
-
Baytown, TX
-
Houston, TX
Business Records
Name / Title
Company / Classification
Phones & Addresses
Director
J International Art Company
Director
Tx Epoch Group Incorporated
7001 Corporate Dr, Houston, TX 77036
President, Director Of Pharmacy
Hester Pharmacy Corp
Mfg Pharmaceutical Preparations · Ret Drugs/Sundries
Mfg Pharmaceutical Preparations · Ret Drugs/Sundries
151155 Hester St, New York, NY 10013
153 Hester St, New York, NY 10013
(212) 966-7599
153 Hester St, New York, NY 10013
(212) 966-7599
VICTOR ENERGY SERVICES LLC
5800 Ranchester Dr #199, Houston, TX 77036
LI'S, INC
404 E 73 St, New York, NY 10021
68-27 Kessel St, Forest Hills, NY 11375
68-27 Kessel St, Forest Hills, NY 11375
XING WANG INTERNATIONAL INC
103-17A 44Th Ave, Corona, NY 11368
Executive
New Peking Restaurant
Eating Place
Eating Place
1137 Washington Ave, Brooklyn, NY 11225
(718) 693-6163
(718) 693-6163
President
NEW WAWA INC
Nonclassifiable Establishments
Nonclassifiable Establishments
7365 Main St, Stratford, CT 06614
17 E Broadway, New York, NY 10002
17 E Broadway, New York, NY 10002
Publications
Isbn (Books And Publications)
Bei Yi Wang De Ying Xiang
View page
Author
Xing Li
ISBN #
7500453027
Us Patents
A Triple-Effect Cocktail Produced By Neural Stem Cells As A Novel Neurorepair Therapy For Chronic Stage Cns Autoimmunity
View pageUS Patent:
20200197487, Jun 25, 2020
Filed:
May 7, 2018
Appl. No.:
16/609882
Inventors:
- Philadelphia PA, US
Yaping Yan - Philadelphia PA, US
Xing Li - Haddonfield NJ, US
Yaping Yan - Philadelphia PA, US
Xing Li - Haddonfield NJ, US
Assignee:
Thomas Jefferson University - Philadephia PA
International Classification:
A61K 38/18
A61K 35/30
A61K 38/17
A61K 38/20
C12N 5/0793
C12N 5/0797
A61P 25/28
A61K 35/30
A61K 38/17
A61K 38/20
C12N 5/0793
C12N 5/0797
A61P 25/28
Abstract:
Treatment of chronic neurodegenerative diseases such as multiple sclerosis (MS) remains a major challenge. Here we genetically engineer neural stem cells (NSCs) to produce a triply therapeutic cocktail comprising IL-10, NT-3, and LINGO-1-Fc, thus simultaneously targeting all mechanisms underlie chronicity of MS in the central nervous system (CNS): persistent inflammation, loss of trophic support for oligodendrocytes and neurons, and accumulation of neuroregeneration inhibitors. After transplantation, NSCs migrated into the CNS inflamed foci and delivered these therapeutic molecules in situ. NSCs transduced with one, two, or none of these molecules had no or limited effect when injected at the chronic stage of experimental autoimmune encephalomyelitis; cocktail -producing NSCs, in contrast, mediated the most effective recovery through inducing M2 macrophages/microglia, reducing astrogliosis, and promoting axonal integrity and endogenous oligodendrocyte/neuron differentiation. These engineered NSCs simultaneously target major mechanisms underlying chronicity of MS and EAE, thus representing a novel and potentially effective therapy for the chronic stage of MS, for which there is currently no treatment available.